| L-AP4 receptor | A type of glutamate receptor that also binds a particular synthetic agonist and acts as a cation channel. (05 Mar 2000) |
|---|---|
| L-arabino-aldose dehydrogenase | <enzyme> Acts on sugars with l-arabino configuration at c2 through c4 Registry number: EC 1.1.1.- (26 Jun 1999) |
| L-arabinose dehydrogenase | <enzyme> See also record for EC 1.1.1.116, d-arabinose dehydrogenase Registry number: EC 1.1.1.46 (26 Jun 1999) |
| L-ascorbate-2-sulfate sulfohydrolase | <enzyme> Analyzed in arylsulfatase a Registry number: EC 3.1.6.- (26 Jun 1999) |
| L-aspartate oxidase | <enzyme> E coli enzyme; forms unstable product, iminoaspartate; b protein of quinolinate synthetase Registry number: EC 1.4.3.16 Synonym: b-protein, quinolinate synthetase, l-aspartate - fumarate oxidoreductase (26 Jun 1999) |
| L-canaline reductase | <enzyme> From leaves of canavalia ensiformis; mw 167 kD; catalyses a NADPH-dependent reductive cleavage of l-canaline to l-homoserine and ammonia Registry number: EC 1.6.6.- Synonym: NADPH-l-canaline oxidoreductase (26 Jun 1999) |
| L-carbamoylase | <enzyme> Hydrolyzes n-carbamoyl amino acids Registry number: EC 3.5.1.- Synonym: amab gene product (26 Jun 1999) |
| l-carnitine | <amino acid> Is a dipeptide - an amino acid made from two other aminos, methionine and lysine. It can be synthesised in the liver if sufficient amounts of lysine, B1, B6 and iron are available. Muscle and organ meat, fish and milk products are the best sources of carnitine in the diet. Carnitine has been shown to have a major role in the metabolism of fat and in the reduction of triglycerides by increasing fat utilisation. It transfers fatty acids across the membranes of the mitochondria where they can be utilised as sources of energy. It also increases the rate at which the liver uses fats. By preventing fatty build-up, this amino acid aids in weight loss and decreases the risk of heart disease. Carnitine has been shown to be deficient in hearts of patients who have died of acute myocardial infections. Muscular dystrophy and myotonic dystrophy have been shown to lead to carnitine loss in the urine and therefore higher requirements for it. Carnitine is stored primarily in the skeletal muscles and heart, where it is needed to transform fatty acids into energy for muscular activity. It is also concentrated in sperm and the brain. Many athletes have noted increased endurance and muscle building with carnitine supplementation. Deficiencies may increase symptoms of fatigue, angina, muscle weakness or confusion. A low level of Vitamin C will also result in apparent Carnitine deficiency. It is contraindicated for people with liver or kidney disease or diabetes It has proven helpful in improving lipid metabolism and reducing elevated total lipids, cholesterol and triglycerides in people with cardiac problems and diabetes, but should only be taken with medical supervision in these conditions. (25 Jun 1999) |
| L-chain disease | bence Jones myeloma |
| L-chain myeloma | bence Jones myeloma |
| l-cone | Long wavelength sensitive cone (red cone). (05 Mar 2000) |
| L-cysteine-cystine C-S lyase | <enzyme> C-des - cysteine desulfhydrase; a pyridoxal phosphate- containing enzyme from synechocystis involved information of fe-s cluster of ferredoxin; catalyses the breakdown of l-cysteine to yield sulfide, pyruvate and ammonia; increased activity with cystine, yielding cysteine persulfide as the primary product; mw about 43 kD Registry number: EC 4.4.1.- Synonym: c-des lyase (26 Jun 1999) |
| L-D body | The intracytoplasmic, nonflagellated leishmanial form of certain intracellular parasites, such as species of Leishmania or the intracellular form of Trypanosoma cruzi; originally used for Leishmania donovani parasites in infected spleen or liver cells in kala azar. Synonym: amastigote, L-D body. (05 Mar 2000) |
| l-dehydroascorbic acid | The reversibly oxidised form of ascorbic acid; it is antiscorbutic, but is converted in the body to 2,3-diketo-l-gulonic acid, which has no vitamin C activity. (05 Mar 2000) |
| l-dopa | <chemical> The naturally occurring form of dopa and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonism and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. Pharmacological action: antiparkinson agents, dopamine agents. (12 Dec 1998) |